Skip to main content
    E

    Exagen Inc (XGN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $5.81
    -1.79 (-23.55%)

    Market Cap: $184.11M

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    79%(22/28)
    Avg Surprise
    -0.65%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.17
    Range$-0.18 - $-0.16
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.14-17.2%
    60d ago$-0.17-3.0%
    30d ago$-0.170.0%
    7d ago$-0.170.0%
    Current$-0.17
    Revenue Consensus
    $18M
    Range$18M - $19M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.04
    Range$-0.04 - $-0.04
    2 analysts
    Revenue Consensus
    $21M
    Range$21M - $22M
    7 analysts
    Last 12 of 29 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.04$-0.04 - $-0.04--2--
    Sep 26EST
    		-$-0.17$-0.18 - $-0.16--2
    0
    1
    30d
    		-
    Jun 26
    Reported Aug 4
    		$-0.13$-0.19$-0.19 - $-0.19+31.58%Beat1
    1
    0
    30d
    		+27.8%
    Mar 26
    Reported May 11
    		$-0.20$-0.25$-0.25 - $-0.25+20.00%Beat2
    1
    2
    30d
    		+0.0%
    Dec 25
    Reported Mar 10
    		$-0.27$-0.18$-0.23 - $-0.17-48.80%Miss6
    0
    3
    30d
    		-33.1%
    Sep 25
    Reported Nov 4
    		$-0.31$-0.16$-0.18 - $-0.14-93.75%Miss4
    0
    1
    30d
    		-10.7%
    Jun 25
    Reported Jul 29
    		$-0.18$-0.15$-0.18 - $-0.12-20.00%Miss5
    0
    3
    30d
    		-12.5%
    Mar 25
    Reported May 5
    		$-0.20$-0.21$-0.23 - $-0.19+4.76%Beat3
    2
    1
    30d
    		-5.3%
    Dec 24
    Reported Mar 11
    		$-0.20$-0.24$-0.30 - $-0.10+16.67%Beat5
    1
    1
    30d
    		+35.5%
    Sep 24
    Reported Nov 12
    		$-0.28$-0.28$-0.32 - $-0.26+0.00%Beat6
    No revisions (30d)
    		+9.7%
    Jun 24
    Reported Aug 5
    		$-0.16N/A-+54.29%Beat6
    1
    0
    30d
    		+42.9%
    Mar 24
    Reported May 13
    		$-0.19$-0.35$-0.40 - $-0.32+45.71%Beat6
    No revisions (30d)
    		+56.8%
    Dec 23
    Reported Mar 18
    		$-0.31$-0.43$-0.48 - $-0.39+27.91%Beat6
    No revisions (30d)
    		+62.7%
    Sep 23
    Reported Nov 13
    		$-0.31$-0.49$-0.50 - $-0.36+36.73%Beat6
    No revisions (30d)
    		+34.0%

    Key Metrics

    Valuation
    P/E Ratio-6.41EV/EBITDAN/A
    Price/FCF-18.50xFCF Yield-5.40%
    Profitability
    Profit Margin-26.60%Operating Margin-8.64%
    ROE-113.80%ROIC-43.94%
    Financial Health
    Debt/Equity1.87xInterest Coverage-3.01x
    Current Ratio3.18xQuick Ratio3.18x
    Trading Statistics
    Beta2.24Avg Volume384.42K
    52-Week High$10.2752-Week Low$2.59

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.96
    SMA 20$7.92
    SMA 50$7.93
    SMA 200$5.10
    EMA 10$7.71
    EMA 20$7.87
    EMA 50$7.66
    EMA 200$6.36

    MACD

    Line: -0.12Signal: 0.03Hist: -0.15

    ADX

    ADX: 21.8+DI: 17.5-DI: 36.6

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down100.0
    PSAR$8.88

    Bollinger Bands

    Upper Band$9.30
    Lower Band$6.54
    %B Position3484%(Upper)
    Band Width-0.27

    RSI (14-Day)

    Oversold
    29.9

    Momentum Oscillators

    Stoch %K37.9
    Stoch %D56.2
    Williams %R-96.2
    ROC (10d)-20.1%
    Momentum-1.46
    CCI (20d)-209.2
    MFI (14d)36.5

    Volatility Measures

    ATR (14d)$0.66(11.3%)
    StdDev (20d)0.69
    Hist Vol111.1%(High)

    Volume Flow

    VWAP$6.47
    OBV3.3M
    AD Line-1.3M
    CMF (20d)-0.206

    Volume Metrics

    Avg Vol (20d)392.2K
    Vol Ratio3.0x(High)
    VWMA (20d)$7.69

    Pivot Points

    R3$9.26
    R2$8.87
    R1$8.24
    Pivot Point$7.85
    S1$7.21
    S2$6.82
    S3$6.19

    Advanced Oscillators

    TSI-5.88
    Ultimate Osc31.7
    KST-20.18

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$19.94M$17.31M$16.63M$17.24M$17.20M$15.50M$13.65M$12.51M$15.06M$14.41M$13.77M$13.42M
    Cost of Revenue$7.72M$7.10M$7.42M$7.17M$6.81M$6.38M$5.18M$5.53M$6.01M$5.82M$5.62M$5.71M
    Gross Profit$12.22M$10.21M$9.21M$10.07M$10.39M$9.12M$8.48M$6.98M$9.06M$8.60M$8.14M$7.71M
    Operating Expenses$13.94M$13.62M$14.18M$13.18M$13.03M$12.49M$11.86M$11.64M$11.64M$11.60M$13.29M$12.78M
    R&D$1.43M$1.55M$1.76M$1.73M$1.48M$1.28M$1.66M$1.48M$1.18M$1.06M$1.08M$1.40M
    SG&A$12.51M$12.07M$12.42M$11.45M$11.54M$11.20M$10.20M$10.16M$10.46M$10.54M$12.22M$11.38M
    Operating Income$-1,722,000$-3,414,000$-4,975,000$-3,100,000$-2,630,000$-3,365,000$-3,383,000$-4,663,000$-2,587,000$-3,003,000$-5,147,000$-5,069,000
    Interest Income$0$0$43,000$3,000$0$0$197,000$197,000$181,000$192,000$173,000$211,000
    Interest Expense$1.20M$1.27M$1.33M$1.32M$1.42M$545,000$563,000$562,000$560,000$549,000$566,000$557,000
    Income Before Tax$-3,196,000$-3,931,000$-4,660,000$-7,086,000$-4,402,000$-3,752,000$-3,749,000$-5,028,000$-2,966,000$-3,360,000$-5,540,000$-5,415,000
    Income Tax Expense$0$36,000$0$1,000$37,000$0$0$0$0$0$0$0
    Net Income$-3,196,000$-3,967,000$-4,673,000$-7,087,000$-4,439,000$-3,752,000$-3,761,000$-5,028,000$-2,966,000$-3,360,000$-5,573,000$-5,415,000
    EBITDA$-1,048,000$-1,271,000$-3,967,000$-4,571,000$-2,254,000$-2,725,000$-2,926,000$-4,207,000$-2,117,000$-2,508,000$-4,603,000$-4,425,000
    EBIT$-1,995,000$-2,664,000$-4,975,000$-5,770,000$-2,983,000$-3,207,000$-3,383,000$-4,663,000$-2,587,000$-3,003,000$-5,147,000$-5,069,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XGN

    News

    Three Healthcare Innovations Earn Gold Honors in 2026 Impact Awards

    Exagen Inc., Qventus, and Welldoc have been recognized with Gold honors in the 2026 Healthcare Innovation Impact Awards for their innovative solutions. Exagen's AVISE platform aids in diagnosing complex autoimmune...

    HCI Innovation Group•11/3/26•Bullish

    Form 4 Exagen Inc: Tina Susan Nova (Director) For: 9 June

    This article reports on a Form 4 filing for Exagen Inc. concerning Director Tina Susan Nova. The filing date is noted as June 9th...

    Investing.com Canada•11/2/26•Neutral

    Exagen (XGN) Analyst Ratings, Stock Forecast and Price Target

    This article provides an overview of Exagen (XGN) stock, including its current analyst ratings, stock forecast, and price targets from various financial firms. It also details recent analyst actions...

    Moomoo•11/1/26•Neutral

    Exagen Inc. (XGN) Seasonal returns chart

    This article from Yahoo Finance provides a seasonal returns chart for Exagen Inc. (XGN). It displays the average monthly price return for the company between 2019 and 2026...

    Yahoo Finance UK•10/31/26•Neutral

    Exagen Inc. (XGN) Seasonal returns chart

    This article provides a seasonal returns chart for Exagen Inc. (XGN), displaying the average monthly price return between 2019 and 2026. The information includes real-time stock prices and historical data...

    Yahoo Finance Australia•10/31/26•Neutral

    XGN Valuation and Fair Value

    P/E
    -6.4x
    P/FCF
    -18.5x
    P/B
    11.5x
    See GNG's fair value

    XGN Profitability: Margins, ROIC and FCF

    Gross margin
    58.6%
    Operating margin
    -8.6%
    Net margin
    -26.6%
    ROIC
    -43.9%
    ROE
    -113.8%
    FCF yield
    -5.4%

    XGN Competitors

    CompanyTicker
    Bright Minds Biosciences IncDRUG
    Mediwound LtdMDWD
    Keros Therapeutics IncKROS
    Inogen IncINGN
    Neuronetics IncSTIM
    Entrada Therapeutics IncTRDA
    Rxsight IncRXST
    Upstream Bio, Inc.UPB

    Sector: Healthcare

    XGN Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    0
    Buy
    7
    Hold
    0
    Sell
    0
    Strong Sell
    0

    XGN Bull Case vs Bear Case

    Bull case

    • XGN grew quarterly revenue 15.9% year over year.
    • 100.0% of XGN's analyst ratings are Buy or Strong Buy.

    Bear case

    • XGN has a -26.6% net profit margin.

    XGN Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -11.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.17
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    XGN Earnings Date

    XGN reports Nov 10, 2026, before the open. The date is confirmed.

    XGN Earnings Call

    The latest XGN earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    XGN ETF Holders

    GNG tracks 3 ETFs that hold XGN. The largest weights:

    1. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    2. Dimensional U.S. Core Equity 2 ETF (DFAC), <0.01% of the fund
    3. Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
    Open the ETF Stock Exposure tool for XGN

    See insider activity

    Frequently Asked Questions About XGN

    When does XGN report earnings?

    Exagen Inc (XGN) is confirmed to report earnings on Nov 10, 2026.

    Does XGN pay dividends?

    Exagen Inc (XGN) does not currently pay a regular dividend.

    What is XGN's market cap?

    Exagen Inc (XGN) has a market capitalization of $184.11M with a current stock price of $5.81.

    Related stocks

    Sector: Healthcare

    All stocks starting with X

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In